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Abstract
Purpose of Review We review the pathophysiology of Shiga-Toxin Enteropathogenic–Hemolytic Uremic Syndrome (STEC-
HUS), strategies to ameliorate or prevent evolution of STEC-HUS, management and the improved recognition of long-term
adverse outcomes.
Recent Findings Following on from the preclinical evidence of a role for the complement system in STEC-HUS, the use of
complement blocking agents has been the major focus of most recent clinical research. Novel therapies to prevent or lessen HUS
have yet to enter the clinical arena. The long-term outcomes of STEC-HUS, similarly to other causes of AKI, are not as benign as
previously thought.
Summary Optimizing supportive care in STEC-HUS is the only current recommended treatment. The administration of early
isotonic fluids may reduce the severity and duration of STEC-HUS. The role of complement blockade in the management of
STEC-HUS remains unclear. The long-term sequelae from STEC-HUS are significant and patients with apparent full renal
recovery remain at risk.
Keywords Haemolytic uraemic syndrome . Prevention . Volume . Saline . Eculizumab
Introduction
Shiga-toxin Enteropathic Hemolytic Uremic Syndrome
(STEC-HUS) presents as a classical thrombotic microangiop-
athy triad consisting of microangiopathic haemolytic anaemia,
thrombocytopenia and renal impairment [1, 2]. Severity
ranges from mild biochemical abnormalities to persisting
end-stage renal disease with a mortality rate of approximately
3% [2]. STEC-HUS poses a significant clinical risk to paedi-
atric patients as the leading primary renal cause of acute kid-
ney injury (AKI) [3]. Proposed therapies to prevent the devel-
opment of STEC-HUS have been studied but their efficacy is
undetermined.
The risk to children of developing renal failure following
STEC-HUS in the short and medium-term is well understood
[4]. However, the long-term risks into adulthood are less well
known, particularly for patients whose renal function appears
to completely recover during the acute episode; it is unclear
whether such patients require any form of long-term
surveillance.
This review will focus on the prevention and treatment
strategies during the initial phase and the long-term outcome
and potential consequences into adulthood for paediatric pa-
tients following STEC-HUS.
Pathophysiology
STEC-HUS is a non-immune, thrombotic microangiopathic
haemolytic anaemia and shares clinical features of the disease
group, thrombotic microangiopathies (TMA). Classically the
smallest vessels, the arterioles and capillaries, are primarily
involved. The disease process is initiated by Shiga-toxin
(stx) on entry into the circulation via endothelial cells. Cell
entry occurs via Gb3 receptors with subsequent disruption of
protein synthesis following inclusion into the endoplasmic
reticulum [3].
Endothelial cell death results in oedema, creating shear
stress within these thickened microvessels; platelet and fibrin
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accumulation further obstructs blood flow [3]. Platelets are
removed from the circulation both by endothelial wall depo-
sition and consumption by the reticulo-endothelial system,
leading to thrombocytopenia [1]. Frictional turbulent flow
through the thickened capillaries causes a mechanical
haemolytic anaemia.
The combination of reduced microcirculatory flow and
anaemia leads tomulti-systemic ischemia. Though this is most
apparent in the kidney, any organ may be affected.
Neurological involvement is common, occurring in approxi-
mately 25% of patients, with pancreatic, gastrointestinal, oc-
ular, cardiac, and pulmonary involvement all described [5–8].
Diagnosis is predominantly clinical, supported by a plausible
source of exposure to E. coli (e.g. farm animals) and by iden-
tification of E. coli; either on stool culture or via positive
antibody on serological testing. Rectal swab analysis by poly-
merase chain reaction may be useful when a stool sample is
not available [9]. Histological confirmation is rarely required.
The role of the complement pathway in STEC-HUS was
first suggested almost half a century ago, with the identifica-
tion that some patients had a low C3 at presentation [10].
Further analysis in small patient cohorts demonstrated in-
creased C3 breakdown products (i.e. C3b, C3c, C3d and
CFB) [11]. C3 was also deposited on 30% of platelet-
leucocyte complexes in patients with STEC-HUS compared
to 12% of healthy controls [12]. Shiga-toxin activates comple-
ment and binds to factor H (an inhibitor to the alternative
pathway) with a reduction in co-factor responsiveness but no
impact on functional ability [13]. More recently, activation of
C3 and C3a deposition in the glomerular basement membrane
has been associated with podocyte dysfunction, with down-
regulation of nephrin and other functional proteins [14].
The combination of clinical and laboratory findings
supporting a role for complement, and the striking impact of
complement blockade in the treatment of the related inherited
condition, atypical HUS (aHUS), has led to therapeutic efforts
targeting complement in the treatment of STEC-HUS [11, 12,
14–17].
Clinical Indicators of E. coli and Risk of Developing
STEC-HUS
The risk of developing STEC-HUS varies internationally and
increases with latitude. The highest incidence is in Argentina
(12–14 per 100,000 persons [18]. The United Kingdom (UK)
has a moderate incidence of 1.2 per 100,000 but this increases
to 4.6 per 100,000 in Scotland; one of the highest rates in the
developed world [18–20]. Different factors affectE. coli trans-
mission including cattle density, commensal carriage rates,
E. coli clade type, rural location, and warm weather followed
by rain. These factors partially explain the seasonality of
STEC-HUS, with the highest incidence occurring between
June and September [1, 21]. One disease-burden modelling
study estimated that there are around 4000 cases of STEC-
HUS annually worldwide resulting in around 250 deaths, with
half of cases occurring in patients under 16 years of age [22]—
that model likely underestimated the true incidence of STEC
infection.
Identifying paediatric patients at initial presentation who
have the greatest risk of adverse outcomes may facilitate early
preventative measures and (where necessary) prompt transfer
to a centre with dialysis provision [23]. It is estimated that
progression from STEC infection to STEC-HUS occurs in
2–14% of sporadic cases and up to 20% in outbreaks [1,
24–26]. Watery diarrhoea is typical following 24–72 h incu-
bation with around 90% progressing to bloody diarrhoea [27].
STEC-HUS typically presents on median day 7 of illness but
can occur up to 14 days following infection, often as GI symp-
toms are improving [2]. Females were at higher risk in some
studies [28] but not consistently [25, 29, 30]. Other presenting
features associated with a greater risk of progression to STEC-
HUS include a history of vomiting, fever and bloody diar-
rhoea although statistical significance varies across studies
[25, 31]. Use of anti-motility agents in the initial illness was
associated with prolonged bloody diarrhoea but did not reach
statistical significance regarding the risk of developing STEC-
HUS [25].
Laboratory findings which are associated with a higher risk
of developing STEC-HUS include an elevated white cell
count > 13 × 109/L and an abnormally high haematocrit
(reflecting intravascular depletion) [2, 25, 32].
Clinical risk scores to identify adults with E. coli gastroen-
teritis who are at greater risk for STEC-HUS have been de-
veloped, however, the applicability of these tools in children is
unknown [31, 33].
Treatment
Supportive therapy remains the mainstay of treatment of
STEC-HUS, managing fluid balance, electrolyte abnormali-
ties and hypertension if present [34]. Up to 80% of patients
will require transfusion with blood or platelets during their
illness [1]. Oligoanuric AKI, fluid overload, refractory
hyperkalaemia or uraemia is supported with renal replacement
therapy (RRT), commonly either peritoneal or haemodialysis.
A single Cochrane review analysing seven randomized
controlled trials (RCTs) showed no benefit of additional
therapies such as plasmapheresis over best supportive care
[34].
Management with Preventative Volume Expansion
There is no standardized clinical approach to fluid manage-
ment in STEC-HUS. In oligoanuric patients, usual manage-
ment is restriction of intake to measured urinary output and
insensible losses. Fluid management of the patient who
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maintains a urine output is influenced by clinical concerns
regarding deterioration in renal function and potential fluid
overload often resulting in conservative rehydration.
However, intravascular depletion may be expected to aggra-
vate any TMA process therefore optimizing hydration could
be beneficial.
An initial study in 2004 prospectively tested the hypothesis
that the microangiopathic process could be ameliorated by
volume expansion leading to improved renal perfusion and
thus reduce progression to oligoanuria [24]. This study iden-
tified that oligoanuric patients received significantly less sodi-
um and overall volume than non-oliguric patients, with in-
creased statistical significance when analysing the first 4 days
of illness. Volume expansion with IV isotonic saline was de-
termined to be potentially nephroprotective, recommending
pre-emptive IV fluid administration in children with con-
firmed E. coli infection [24]. It was notably suggested that
oral fluids were not an adequate substitution for IV hydration
[24].
A multicentre prospective observational cohort study ex-
plored this further, confirming the benefits of IV fluid admin-
istration in the first 4 days. 84% of patients who did not re-
ceive IV fluids developed oligoanuria, compared to 52% who
did (relative risk(RR) of 1.6 (CI 1.1–2.4)) [35]. The median
volume of IV fluid given was 1.7 l/m2, and no patients devel-
oped fluid overload. Though that study supported the recom-
mendation for early administration of isotonic saline, no com-
ment was made on duration, rate or volume of fluid.
Two later retrospective observational studies evaluated the
relationship between dehydration and outcome. One study
found clinically dehydrated patients (defined by World
Health Organization classification) were more likely to re-
ceive RRT; 71% in the dehydrated group compared to 41%
of adequately hydrated patients. The number of dialysis days
was 50% higher, (12 versus 8 days), suggesting reduced intra-
vascular volumemay exacerbate or accelerate the STEC-HUS
disease process [32]. The second study associated high
haematocrit at presentation with poorer neurological outcome
[36]. As neurological involvement in HUS is strongly associ-
a t ed wi th mor ta l i ty, i t may be specu la ted tha t
haemoconcentration and decreased intravascular volume
may be similarly associated. The same authors subsequently
reported a relationship between IV volume expansion and
improved overall outcome on retrospective review, with re-
duction in need for dialysis, intensive care, development of
neurological sequelae and less hospital days [37].
A meta-analysis including the above studies identified
benefit of IV fluids up until the day of development of
STEC-HUS with an association with reduced need for
RRT (Odds Ratio(OR) 0.26 [95% 0.11–0.6]) and a
haematocrit > 23% was associated with increased risk of
oligoanuric STEC-HUS (OR 2.38), RRT (OR 1.9) and
death (OR 5.13) [38••].
The evidence to support IV fluid hydration in the prodro-
mal phase of STEC-HUS continues to grow, yet fluid hydra-
tion in at-risk children is not widely practiced. In centres with
a high-risk of STEC-HUS, 40% of patients who developed the
syndrome attended paediatric emergency departments early in
the disease, however, stool culture and pre-emptive IV fluid
administration have not improved over the last 17 years [39•].
There is a need for increased awareness in early identification
of E. coli and initiation of IV fluid therapy in primary and
secondary care to reduce disease burden globally [39•].
IV fluid administration in the context of STEC infection
does require close monitoring for development of renal im-
pairment and fluid overload and there is an associated cost
implication of admission for hydration; however, this should
be balanced with the significant morbidity of CKD, ESRD
and death. In the absence of curative STEC treatment, com-
paring different rates of IV fluids would be important to re-
duce the progression of STEC-HUS, and could be addressed
by an RCT.
Antibiotics
The role of antibiotics in STEC-HUS remains unclear.
Worsening of disease is hypothesised to occur following anti-
biotic administration due to either the widespread release of
Shiga-toxin following bacterial cell death, or alteration of the
commensal gut flora allows Shiga-toxin to freely attach to the
intestinal wall. The contrasting hypothesis is that earlier de-
struction of E. coli leads to reduced excretion of Shiga-toxin
and subsequently decreased severity of STEC-HUS.
Understanding is complicated further by the differential ef-
fects of various antimicrobial agents on different strains of
E. coli. Study heterogeneity presents challenging evaluation
of results; indeed, meta-analyses of the same combined co-
horts can reach opposing conclusions [40, 41, 42•, 43].
Several papers have shown no association between antibi-
otic use and development of STEC-HUS secondary to E. coli
O157 [25, 44, 45]. An RCT in 47 paediatric patients analysed
trimethoprim use in E. coli 0157 and showed no significant
progression to STEC-HUS, symptomatic improvement or
change in Shiga-toxin excretion [44]. Although antibiotic
use in hospital did not reach statistical significance as a risk
factor for STEC-HUS, pre-hospital administration of antibi-
otics was associated with increased risk [45].
Increased risk was also identified in a 15-year study of
STEC-HUS incorporating 783 patients aged < 18 years, in
whom recent respiratory tract infection and treatment with
antibiotic was associated with an increased mortality [2]. In
a prospective study of 71 paediatric patients with E. coli
0157:H7, antibiotic use was a risk factor for progression to
STEC-HUS [46]. Bactericidal antibiotics, (in particular ß-
lactams) administered in the first 3 days of illness was associ-
ated with increased risk of STEC-HUS in a case-control study
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of 195 patients (OR 12.4 and 11.3) [47]. One study comparing
the response of different E. coli subtypes to antibiotic therapy
(namely, ciprofloxacin, meropenem, fosfomycin or chloram-
phenicol) showed release of Shiga toxin following antibiotics
by E. coli O157:H7 but not subtype O104:H4 [48].
An in vivo mouse model using E. coli O86 demonstrat-
ed decreased Shiga-toxin production and reduced mortal-
ity following administration of azithromycin [49].
Following the large German E. coli 0104:H4 outbreak, a
retrospective analysis identified that use of azithromycin
reduced duration of Shiga-toxin excretion in stool [50].
Other retrospective analysis of the same outbreak identi-
fied patients treated with dual antibiotic therapy (specifi-
cally ciprofloxacin and meropenem IV) significantly
shortened the duration of excretion of Shiga-toxin in
stool, with a concomitant lower incidence of seizures
and death compared to patients who did not receive anti-
biotics [51]. Confounding factors included the absence of
criteria for commencing antibiotics or whether the sever-
ity of disease influenced antibiotic administration [51]. A
further sub-analysis of the outbreak found significant re-
duction in STEC-HUS development with ciprofloxacin
though this was under-powered to definitively reach a
conclusion [52]. A multicenter observational study of
fosfomycin use in STEC infection identified a possible
reduction to progression to STEC-HUS when given with-
in the first 5 days but would benefit from supporting
studies(OR 0.15 [95%CI 0.05–0.45]) [53].
One meta-analysis did not find an association between an-
tibiotic use and STEC-HUS [43]. Exclusion of studies at high
risk of bias in a more recent meta-analysis conversely con-
cluded that antibiotic use was associated with increased risk of
STEC-HUS [42•]. In contrast, a systematic review identified
the potential benefit of antibiotics, namely azithromycin, in
inhibiting cell wall and protein synthesis and recommended
use in specific circumstances [41].
A consensus on antibiotics has not been established. It is
likely that differential effects are seen between microbial
strains and choice of antibiotic. Use of antimicrobials should
be considered on an individual and strain basis only when
benefit is thought likely. Future characterization of the strain
response, in particular during outbreaks may permit more in-
formed decisions [48].
Platelet Transfusion
Platelet transfusion has historically been relatively contraindi-
cated in STEC-HUS due to the theoretical potential to aggra-
vate the thrombotic microangiopathy, administration being
restricted to transfusion immediately preceding surgical inter-
ventions and in response to significant haemorrhage or muco-
sal bleeding. Two retrospective case-control studies [54, 55],
demonstrated no differences comparing patients who did or
did not receive platelets in disease severity, neurological com-
plications, requirement for intensive care, or mortality. A
small rise in inflammatory markers was noted following plate-
let transfusion in the second study; these returned to baseline
[55]. It was also noted that 6 patients died during the German
E. coli 0104:H4 outbreak from procedure-related bleeding
[55]. Though larger studies are required to fully reassure, the
risks of platelet transfusion may not be as high as previously
theorized, and may confer clinical benefit, especially in pa-
tients at greater risk of haemorrhage [55].
Eculizumab
Eculizumab is a monoclonal antibody that targets complement
C5b and is a licenced effective treatment for aHUS, which
shares many disease features with STEC-HUS. This prompted
further investigation into a possible role in the management of
STEC-HUS.
In a case series of three patients in 2011, severe neurolog-
ical involvement led to compassionate treatment with
eculizumab. There was resolution of neurological findings
within 24 h and improvement of platelets and lactate dehydro-
genase (LDH) within 5 days [56]. This led to increased ‘com-
passionate’ use in some centres, especially where neurological
involvement was considered severe, with an escalation of us-
age during the outbreak of E. coli O104:H4 in 2011.
That outbreak dominates the current literature surrounding
the use of eculizumab in the treatment of STEC-HUS. The
differential ability of centres to provide eculizumab alongside
plasmapheresis led to a natural nested cohort study, admittedly
with many confounding factors [57]. Unadjusted analyses
suggested a higher mortality in the best supportive care cohort,
but there was an evident selection bias with a predominance of
elderly patients. Treatment allocations were by clinician
choice and not randomized or age-matched. When consider-
ing severity matched cohorts, there was no evidence for addi-
tional benefit from plasmapheresis and eculizumab over sup-
portive care [57].
A further retrospective analysis of this cohort of 298 pa-
tients reviewed 67 patients who received eculizumab [51]
(Table 1). This cohort presented with more severe disease
compared to those in other treatment arms. When matched
for severity using patients receiving plasmapheresis, there
was no difference in complication rates or recovery time of
biochemical markers of HUS. There was no best supportive
care model available for comparison [51].
Smaller cohorts from the same outbreak have also been
reported from France. A nine patient case series, all receiving
plasmapheresis, reported eculizumab administration with neu-
rological and biochemical improvement in all patients [8].
Azithromycin prophylaxis was administeredwith eculizumab,
which as described may also lead to earlier reduction of faecal
Shiga-toxin in E. coli 0104:H4 [51].
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A small study of seven patients receiving eculizumab for
treatment of STEC-HUS described the reversibility of
Magnetic Resonance Imaging (MRI) cerebral abnormalities
in the initial phase of disease when revisited at 6 months
[58]. This was a small uncontrolled observational study,
MRI scan in the acute phase may be normal despite severe
disease and the natural course of transient neurological find-
ings is resolution [66–68], so evidence of definitive benefit is
lacking.
Another analysis of 33 French children in the E. coli O104
outbreak (which included seven patients from the above co-
hort) separated patients retrospectively into groups with a
favourable or unfavourable outcome [63]. Analysis of com-
plement blockade at follow-up showed a higher degree of
complement blockade in the favourable outcome group (11/
14 [79%] versus 9/15 [53%]). The difference between the two
groups did not reach significance. Several limitations in that
report (e.g. unclear exclusion criteria) prevent any firm con-
clusion of clinical benefit [67, 69]. There is no evidence to
date that persistence of complement blockade at 6 months
relates to the efficacy of eculizumab in an acute phase of
illness [63].
A retrospective case series from Istanbul reported nine pae-
diatric patients with STEC-HUS treated with eculizumab at
the discretion of the clinician at a median of 12 days (1–
49 days)—in some cases, after the requirement for RRT had
resolved [64]. Baseline characteristics between groups were
similar but no descriptor for dialysis requirement or maximal
creatinine was reported. Two patients treated with eculizumab
were reported to have a reduction in blood product require-
ments and one child had resolution of neurological involve-
ment and dialysis requirements within 48 h. One child died at
day 50 from Gram-negative sepsis following five eculizumab
doses [64]. The wide variation and timing of eculizumab ad-
ministration, loss to follow-up and unclear severity compara-
tors limit the applicability of these data [64].
A recent paediatric retrospective matched control study
from France described 18 patients receiving Eculizumab in a
single centre. No benefit of Eculizumab was found on renal
outcome, however possible benefit was identified in the treat-
ment of neurological STEC-HUS [65•].
Multiple narrative reviews attempting to establish the effi-
cacy of eculizumab in the treatment of STEC-HUS have not
established benefit. The need for large RCTs has been recog-
nized, with two such trials now underway [16, 70]. The UK-
based ECUSTEC trial is a double-blind RCT recruiting pa-
tients with STEC-HUS to receive eculizumab or saline-based
placebo [71••]. The primary aim of the trial is to assess wheth-
er early administration of eculizumab will reduce a composite
score for severity of STEC-HUS and secondary aims will
assess the presence of CKD, neurological sequelae and
health-related quality of life at 1 year [71••]. ECULISHU in
France is a single-blind RCT to eculizumab or dextrose-based
placebo, with patients who deteriorate on placebo converted to
the eculizumab arm of the trial [72]. The primary outcome is
the duration of acute dialysis. Secondary aims include devel-
opment of CKD, haematological abnormalities, duration of
complement blockade and effect on terminal complement
complex (TCC) up to 1 year post-STEC-HUS. The results of
these trials will better inform whether eculizumab has a role in
the treatment of STEC-HUS.
Long-term Outcome
Previously, a return to normal renal function after an acute
episode of STEC-HUS was felt to have no ongoing sequelae.
More recent longitudinal data on patient cohorts with previous
AKI of any cause demonstrates that the risks of further renal
dysfunction persist over time. [73].
One meta-analysis reviewing the development of long-
term renal sequelae after STEC-HUS (with a minimum of
12 months from acute disease onset) reported mortality or
end-stage renal disease (ESRD) in 0–30% of patients. Up to
64% of patients developed abnormal GFR, proteinuria or hy-
pertension [4]. Included studies had notable heterogeneity,
including importantly the duration of follow-up, with fewer
studies persisting into adulthood.
A small cohort of 29 patients examined long-term follow-
up into adulthood (15–25 years). Ten patients had no renal
sequelae; the remaining 19 developed renal dysfunction (iso-
lated hypertension n = 7, proteinuria n = 4) with four reaching
ESRD [74]. That cohort also reported that an acute require-
ment for RRT did not predict either subsequent CKD or those
at long-term risk [74]. That finding has been replicated in
other studies; deterioration in GFR occurring in patients not
requiring dialysis during the acute illness [75, 76].
One study reported only those patients who did not require
RRT (n = 130, mean follow-up 12.2 years), demonstrating a
lower rate of sequelae, with 15% of patients developing hy-
pertension or proteinuria, and 6% developing an abnormal
GFR but no patients reaching ESRD [77].
A medium-term longitudinal study of an initial cohort of
114 patients described progression of CKD in relation to GFR
at 1 year. 66 of 92 patients (72%) had a normal GFR at 1 year.
Follow-up data were available for 40 patients at 5 years. Six
patients with a previously abnormal GFR had normalized,
whilst three additional patients had developed abnormal
GFR in the interim period [76]. Using data from the 2011
European O104 outbreak available for 72 patients at a mean
follow-up of 3 years, GFR improved in two of four patients
with a previous abnormal GFR; one GFR normalized and a
further two patients improved from CKD four to three [62].
These studies demonstrate that patients with less severe initial
disease may still be at risk of long-term renal sequelae, con-
sistent with other AKI literature.
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Sub-clinical STEC-HUS may occur in patients not under-
going renal evaluation during the acute STEC infection.
Following the E. coli O157 Walkerton outbreak in Ontario,
epidemiological studies (n = 1977) identified an increased risk
for hypertension, abnormal GFR and self-reported cardiovas-
cular disease when compared to unexposed matched case con-
trols (HR 1.33, 1.15 and 2.13) [78]. These findings were not
replicable in a smaller 19 patient paediatric cohort when com-
pared to matched controls 4 years post initial illness [79].
STEC-HUS occurs more rarely in adult populations, and the
smaller paediatric sample size, or greater plasticity of paediat-
ric patients may contribute to the disease differences.
There are data supporting the supposition that children with
a ‘full’ renal recovery have ongoing detectable manifestations
of renal disease. Two small papers assessed the capacity for
hyperfiltration through protein loading and identified a
blunting in this response—those authors proposed that this
mechanism may contribute to ongoing vulnerability to CKD
despite normalization of renal function, with patients behav-
ing similarly to those with a solitary kidney [80, 81].
Abnormal endothelial function of skin microvasculature using
Doppler fluximetry was found in 50% of patients who ap-
peared to have fully recovered renal function following
STEC-HUS and were normotensive [82]. Clarifying the un-
derlying pathogenesis for these persisting abnormalities may
assist in informing future therapies.
Potential Future Therapies
The mainstay of care remains supportive during an acute ep-
isode of STEC-HUS and is predominantly reactive once the
disease process is recognized. Both the trials of eculizumab
(detailed extensively previously) are also reactive, though
with the intention of intervention in the earlier stages of the
illness. An alternative target is the immediate response to the
toxin itself.
An RCT of an oral Shiga-toxin binding agent showed no
benefit, potentially indicating the toxin may have caused
established damage during the time delay between symptom
onset and identification of STEC infection [83]. The develop-
ment of monoclonal antibodies against Shiga-toxin 2 (Stx2)
has shown some promise in animal models. A piglet model
showed neurological benefit of urtoxazumab when adminis-
tered 24 h following STEC administration [84], with phase I
trials confirming safety of urtoxazumab in a relevant patient
population [85]. As yet, clinical efficacy has not been con-
vincingly demonstrated. Research efforts to develop agents
for neutralization of Shiga-toxin are ongoing, such as the de-
velopment of humanized recombinant antibody fragments di-
rected against Stx2 which effectively neutralize cytotoxicity
in vitro [86].
Rather than a reactive response, proactively preventing in-
fection through vaccination has been considered [87]. Early
approaches to targeting Shiga-toxin 2b (Stx2b) were promis-
ing but proved difficult to translate to humoral immunity
[88–90]. This led to the development of novel genetic ap-
proaches, using bacterially derived DNA [91]. This approach
uses regulatory gene elements which cause antigenic re-
sponses to Stx2B. Though apparently effective in mouse vac-
cination models, further research was limited by technical is-
sues with production of recombinant Stx2B including inherent
instability [92]. Mucosal immunity is an alternative target for
therapies as it plays a key role in the pathogenicity of stx. A
chimeric protein OmpA-LTB with the ability to bind against
the intestinal wall when taken orally allows an immunogenic
response to E. coli 0157:H7 to be mounted in silico [93•].
Targeting outer membrane vesicles (OMVs) produced by
E. coli O157:H7 has been successfully explored using eye-
drop administration in mice [94]. More recently, approaches
targeting OMVs have also been tested in cattle and proved
effective, providing encouraging results for future human
use [95].
Conclusions
Best supportive care remains the mainstay of treatment of
STEC-HUS in paediatric patients. Volume expansion with
isotonic saline may be considered in patients with probable
STEC, though use is most effective in the first 4 days of
symptoms. The role of antibiotics in STEC-HUS remains
unclear—trials incorporating analysis by strain may be neces-
sary. Complement blockade is increasingly used, though ro-
bust supportive evidence is absent; two ongoing trials may
clarify this.
The long-term outcome of STEC-HUS is less optimistic
than earlier reports suggested, as longitudinal follow-up re-
veals patients remain at risk into adulthood. Recognition
may allow earlier management of proteinuria and
hypertension.
At present, prevention of STEC infection remains the best
strategy for reducing complications of STEC-HUS.
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